Compare BNR & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNR | OABI |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | China | United States |
| Employees | N/A | 89 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.7M | 237.4M |
| IPO Year | 2019 | N/A |
| Metric | BNR | OABI |
|---|---|---|
| Price | $16.86 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 23.7K | ★ 547.8K |
| Earning Date | 06-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $111.65 | $52.42 |
| Revenue Next Year | N/A | $64.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.18 | $1.22 |
| 52 Week High | $41.72 | $2.22 |
| Indicator | BNR | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 39.04 | 36.71 |
| Support Level | $15.61 | $1.32 |
| Resistance Level | $23.19 | $1.70 |
| Average True Range (ATR) | 1.60 | 0.09 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 14.93 | 3.92 |
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.